Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD Study
核心洞察
Polarean (搜索) announced expansion of its Xenon MRI platform into cardiopulmonary pharma-sponsored drug development through a multi-center U.S. study in pulmonary hypertension with interstitial lung disease (搜索) (PH-ILD (搜索)).
The researcher-led study will use Xenon MRI-derived biomarkers to evaluate an inhaled therapy designed to address both pulmonary vascular dysfunction and interstitial lung disease (搜索).
Xenon MRI is the only imaging modality that specifically probes pulmonary capillaries (搜索), previously a "silent zone" that could not be measured directly with existing diagnostic tools.
Polarean (搜索), a commercial-stage medical imaging company, announced the expansion of its Xenon MRI platform into cardiopulmonary pharmaceutical drug development through a multi-center U.S. study targeting pulmonary hypertension with interstitial lung disease (搜索) (PH-ILD (搜索)). The researcher-led study, funded by a leading cardiopulmonary pharmaceutical company, will use Xenon MRI-derived biomarkers to evaluate an inhaled therapy designed to address both pulmonary vascular dysfunction and interstitial lung disease (搜索).
Revolutionary Imaging Technology Addresses Critical Gap
Xenon MRI represents a breakthrough in cardiopulmonary imaging as the only modality that specifically probes the smallest part of the heart-lung vascular circuit: the pulmonary capillaries (搜索). This region has historically remained a "silent zone" of lung function that could not be measured directly with existing tools such as right-heart catheterization or V/Q (ventilation-perfusion) scans, which rely on indirect inference of capillary pressures, flow, blood volume, and oxygen transfer efficiency.
The xenon gas follows the same path as oxygen and can enter micron-level spaces to assess treatment-induced physiological changes across the lung parenchyma and capillary bed where oxygen is delivered to the blood. This enables noninvasive, radiation-free quantitative imaging that supports early pharmacodynamic readouts in clinical studies, differentiation between inhaled and systemic therapies based on mechanism of action, improved patient characterization, and greater endpoint sensitivity in cardiopulmonary clinical trials.
Innovative Trial Design Captures Real-Time Drug Effects
The study employs an innovative design to capture both acute (within minutes) and chronic (over 12 weeks) treatment effects using Xenon MRI to quantify regional changes in lung ventilation, gas diffusion across the interstitial membrane, pulmonary capillary blood volume, and microvascular hemodynamics.
"There are encouraging recent data on prostacyclin analogues (搜索) in fibrotic lung disease (搜索), both in patients with and without pulmonary hypertension (搜索). It will be interesting to see whether Xenon MRI gas-exchange imaging can help elucidate if early antifibrotic changes in interstitial membrane function can be visualized and quantified noninvasively," said Arun Jose, MD, MS, an investigator in the study from the University of Cincinnati.
Sudar Rajagopal, MD, PhD, a cardiologist investigator from Duke University (搜索), noted that "This study builds on our prior work using Xenon MRI to evaluate early treatment effects in pulmonary hypertension (搜索). Assessing regional lung pharmacodynamics within minutes of inhalation may help clarify how inhaled therapies exert local pulmonary effects distinct from systemic mechanisms."
Addressing Significant Unmet Medical Need
PH-ILD (搜索) represents a severe, progressive condition characterized by pulmonary vascular remodeling in the setting of interstitial lung disease (搜索). Patients experience marked exercise limitation, worsening dyspnea, and significantly reduced survival. In the United States, PH-ILD affects tens of thousands of patients, with prevalence increasing substantially as ILD progresses.
The condition reflects inefficient capillary oxygenation driven by both parenchymal disease, where interstitial membrane thickening impairs gas diffusion, and pulmonary microvascular dysfunction, where blood flow is restricted. This dual pathology makes PH-ILD (搜索) particularly challenging to study, diagnose, and treat, contributing to poor outcomes when pulmonary hypertension (搜索) develops.
Overcoming Limitations of Conventional Diagnostic Tools
Current diagnostic approaches provide fragmented views of PH-ILD (搜索) pathophysiology. Standard CT imaging characterizes structure but cannot visualize function in the smallest units of the pulmonary capillaries (搜索). Right-heart catheterization, while providing pressure measurements, is invasive and does not assess regional gas exchange at the alveolar level. Pulmonary function tests lack cardiovascular insight, spatial resolution, and sensitivity needed to detect early or localized disease.
"This collaboration heralds the expanding role of Xenon MRI as a cardiopulmonary imaging platform for drug development. By providing novel, noninvasive biomarkers of pulmonary vascular and interstitial disease in a single 10-second breath hold, Xenon MRI can help accelerate clinical development. This can result in savings of both time and cost, allow industry partners to visualize the microvascular effects of their treatments, and de-risk therapeutic programs in areas of significant unmet need," said Alex Dusek, Chief Business Officer of Polarean (搜索).
Platform Expansion and Clinical Impact
Polarean (搜索) is collaborating with VIDA Diagnostics (搜索) to provide centralized imaging operations, site orchestration, and advanced Xenon MRI biomarker analysis for the study. The company has developed XENOVIEW, the first and only FDA-approved hyperpolarized Xenon-129 (搜索) MRI inhaled contrast agent, which is indicated for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older.
The expansion into cardiopulmonary drug development positions Xenon MRI as a differentiated platform to support patient characterization, therapeutic development, and more sensitive clinical trial design in PH-ILD (搜索) and other cardiopulmonary conditions affecting more than 500 million patients worldwide.